Antimicrobial resistance, virulence profile, and genetic analysis of ESBL-producing Escherichia coli isolated from Nile tilapia in fresh markets and supermarkets in Thailand
Author:
Hinthong Woranich,
Thaotumpitak VarangkanaORCID,
Sripradite JarukornORCID,
Indrawattana Nitaya,
Srisook Thassanee,
Kongngoen Thida,
R. Atwill Edward,
Jeamsripong SaharuetaiORCID
Abstract
This study investigated the prevalence and antimicrobial resistance (AMR) of Escherichia coli (E. coli) in Nile tilapia from fresh markets and supermarkets. A total of samples (n = 828) were collected from Nile tilapia including fish flesh (n = 276), liver and kidney (n = 276), and intestine (n = 276). Overall prevalence of fecal coliforms (61.6%) and E. coli (53.0%) were observed. High prevalence of E. coli was found in the intestine (71.4%), followed by the liver and kidney (45.7%). The highest prevalence of resistance was commonly found against tetracycline (78.5%), ampicillin (72.8%), and sulfamethoxazole (45.6%) with resistance to only tetracycline (15.2%) as the most common antibiogram. The prevalence of multidrug resistance (MDR) (54.4%) and Extended-spectrum beta-lactamases (ESBLs) (5.7%) were examined. The predominant virulence genes (n = 158) were st (14.6%), followed by eaeA (0.6%). The blaTEM (73.4%), tetA (65.2%), and qnrS (57.6%). There is statistical significance between Nile tilapia from fresh markets and supermarkets. Based on logistic regression analysis, ampicillin-resistant E. coli was statistically associated with the phenotypic resistance to tetracycline and trimethoprim, and the presence of blaTEM and tetA (p < 0.05). Further investigation of AMR transference and their mechanisms is needed for AMR control.
Funder
Thailand Science Research and Innovation Fund at Chulalongkorn University
National Research Council of Thailand
University of California, Davis
Thailand Science Research and Innovation, and Thailand Research Fund
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference60 articles.
1. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis;Z Golkar;J. Infect. Dev. Ctries,2014
2. Centers for Disease Control and Prevention (CDC), 2019. Antibiotic resistance threats in the United States. Atlanta, GA: U.S. Department of Health and Human Services. Available from https://stacks.cdc.gov/view/cdc/82532 (accessed December 7, 2023).
3. O’Neill J. 2016. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. Government of the United Kingdom. http://amr-review.org/sites/default/files/160525Final%20paperwith%20cover.pdf (accessed February 17, 2022).
4. Health and economic impacts of antimicrobial resistant infections in Thailand: a preliminary study;P Phumart;J. Health Serv. Res. Policy,2012
5. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use;P Shrestha;Antimicrob. Resist. Infect. Control,2018